Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

Dabrafenib is an oral BRAF kinase inhibitor approved for the treatment of various BRAF V600 mutation–positive solid tumors. In vitro observations suggesting cytochrome P450 (CYP) 3A induction and organic anion transporting polypeptide (OATP) inhibition prompted us to evaluate the effect of dabrafeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Nebot, Noelia, Won, Christina S., Moreno, Victor, Muñoz‐Couselo, Eva, Lee, Dung‐Yang, Gasal, Eduard, Bouillaud, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453865/
https://www.ncbi.nlm.nih.gov/pubmed/33932130
http://dx.doi.org/10.1002/cpdd.937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453865/
https://www.ncbi.nlm.nih.gov/pubmed/33932130
http://dx.doi.org/10.1002/cpdd.937

Ejemplares similares